Sanofi India Ltd
Company Profile
- Business description- Sanofi India Ltd is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. It focuses on a range of therapeutic areas, including diabetes, cardiology, consumer healthcare, hospital, central nervous system, and anti-histamines, among others, and sells its products through independent distributors predominantly in India. The company's products are manufactured in different types of dosage forms, including tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams, and ointments, and are marketed under different brand names such as Soframycin, Lantus, Cardace, Soliqua, Solian, Thyrogen, Telcite, Zolineg, etc. Geographically, the company generates a majority of its revenue from India, followed by Singapore, and other export markets. 
- Contact- Saki Vihar Road 
 Sanofi House, CTS Number 117-B
 L&T Business Park
 Powai
 MumbaiMH400072
 IND- T: +91 2228032000 
- Sector- Healthcare - Stock type- Defensive 
- Industry- Drug Manufacturers - General - Fiscal Year End- 31 December 2025 - Employees- 1,285 
Stocks News & Analysis
stocks
Microsoft earnings: Strong, including Azure, but overall guidance is in line
stocks
After earnings, is Tesla stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
| Index | Last price | Change | % Change | 
|---|---|---|---|
| All Ordinaries | 9,178.00 | 28.70 | -0.31% | 
| CAC 40 | 8,121.07 | 36.22 | -0.44% | 
| DAX 40 | 23,958.30 | 160.59 | -0.67% | 
| Dow JONES (US) | 47,502.14 | 19.98 | -0.04% | 
| FTSE 100 | 9,717.25 | 42.81 | -0.44% | 
| HKSE | 25,906.65 | 376.04 | -1.43% | 
| NASDAQ | 23,723.77 | 142.63 | 0.60% | 
| Nikkei 225 | 52,411.34 | 1,085.73 | 2.12% | 
| NZX 50 Index | 13,548.32 | 89.03 | 0.66% | 
| S&P 500 | 6,839.13 | 16.79 | 0.25% | 
| S&P/ASX 200 | 8,881.90 | 31.30 | -0.35% | 
| SSE Composite Index | 3,954.79 | 32.11 | -0.81% |